Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Nature Communications|August 23, 2019
Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease modelElizabeth Spangenberg, Paul L Severson, Lindsay A Hohsfield, et al.Proceedings of the National Academy of Sciences of the United States of America|March 16, 2013
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitorChao Zhang, Prabha N Ibrahim, Jiazhong Zhang, et al.Cancer Discovery|April 8, 2015
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397Catherine C Smith, Chao Zhang, Kimberly C Lin, et al.JAMA Oncology|July 8, 2021
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical TrialAndrew J Wagner, Paul L Severson, Anthony F Shields, et al.Nature|October 16, 2015
RAF inhibitors that evade paradoxical MAPK pathway activationChao Zhang, Wayne Spevak, Ying Zhang, et al.Nature|September 9, 2010
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, Peter Hirth, James Tsai, et al.Cancer Discovery|February 2, 2018
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET InhibitorHatice Gulcin Ozer, Dalia El-Gamal, Ben Powell, et al.Pageof 1